Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer

International Journal of Oncology

Volumn 34, Issue 2, 2009, Pages 345-353

  Nakamura, Keiichiro ^a   Abarzua, Fernando ^a   Kodama, Junichi ^a   Hongo, Atsushi ^a   Nasu, Yasutomo ^a   Kumon, Hiromi ^a   Hiramatsu, Yuji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptotic pathway; Favorable prognosis marker; HAI 1; HAI 2; Ovarian cancer

Indexed keywords

HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 2; HEPSIN; MATRIPTASE; MEMBRANE PROTEIN; PROTEIN BAK; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARIECTOMY; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR VOLUME;

APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SERINE ENDOPEPTIDASES; SURVIVAL ANALYSIS;

EID: 64549159005     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000157     Document Type: Article

References (30)

1. Jeffers M, Rong S and Vande Woude GF: Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 16: 1115-1125, 1996.
2. Comoglio PM: Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. EXS 65: 131-165, 1993.
3. Rosen EM, Nigam SK and Goldberg ID: Scatter factor and the c-Met receptor: a paradigm for mesenchymal/epithelial interactions. J Cell Biol 127: 1783-1787, 1994.
4. Ayhan A, Ertunc D, Tok EC and Ayhan A: Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance. Int J Gynecol Cancer 15: 618-623, 2005.
5. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS and Lengyel E: c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67: 1670-1679, 2007.
6. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K and Kitamura N: Hepatocyte growth factor activator nhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 272: 6370-6376, 1997.
7. Kawaguchi T, Qin L, Shimomura T, Kondo J, Matsumoto K, Denda K and Kitamura N: Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 272: 27558-27564, 1997.
8. Kataoka H, Itoh H, Nuki Y, Hamasuna R, Naganuma S, Kitamura N and Shimomura T: Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator. Biochem Biophys Res Commun 290: 1096-1100, 2002.
9. Müller-Pillasch F, Wallrapp C, Bartels K, Varga G, Friess H, Büchler M, Adler G and Gress TM: Cloning of a new Kunitz-type protease inhibitor with a putative transmembrance domain overexpressed in pancreatic cancer. Biochim Biophys Acta 1395: 88-95, 1998.
10. Hamasuna R, Kataoka H, Meng JY, Itoh H, Moriyama T, Wakisaka S and Koono M: Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells. Int J Cancer 93: 339-345, 2001.
11. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K and Koono M: Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 275: 40453-40462, 2000.
12. Lin CY, Anders J, Johnson M and Dickson RB: Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 274: 18237-18242, 1999.
13. Kataoka H, Hamasuna R, Itoh H, Kitamura N and Koono M: Activation by hepatocyte growth factor/scatter in colorectal carcinoma. Cancer Res 60: 6148-6159, 2000.
14. Parr C, Watkins G, Mansel RE and Jiang WG: The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 10: 202-211, 2004.
15. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF and Mukhtar H: A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 15: 217-227, 2006.
16. Nagaike K, Kohama K, Uchuyama S, Tanaka H, Chijiiwa K, Itoh H and Kataoka H: Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. Cancer Sci 95: 728-735, 2004.
17. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y and Osada Y: Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol 171: 890-896, 2004.
18. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, Al-Nafussi A, Smyth JF, Gabra H and Sellar GC: Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 8: 1101-1107, 2002.
19. Fukai K, Yokosuka O, Chiba T, Hirasawa Y, Tada M, Imazeki F, Kataoka H and Saisho H: Hepatocyte growth factor activator inhibitor 2/placental bikunin HAI-2/PB gene is frequently hypermethylated in human hepatocellular carcinoma. Cancer Res 63: 8674-8679, 2003.
20. Betsunoh H, Mukai S, Akiyama Y, Fukushima T, Minamiguchi N, Hasui Y, Osada Y and Kataoka H: Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci 98: 491-498, 2007.
21. Marlor CW, Delaria KA, Davis G, Muller DK, Greve JM and Tamburini PP: Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two kunitz domains. J Biol Chem 272: 12202-12208, 1997.
22. Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Suzuki M and Terao T: Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer. Gynecol Oncol 94: 725-734, 2004.
23. Netzel-Arnett S, Hooper JD, Szabo R, Madison EL, Quigley JP, Bugge TH and Antalis TM: Membrane anchored serine proteases: a rapidly expanding group of cell surface proteolytic enzymes with potential roles in cancer. Cancer Metast Rev 22: 223-236, 2003.
24. Lee SL, Dickson RB and Lin CY: Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 275: 36720-36725, 2000.
25. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR and Craik CS: Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 275: 26333-26342, 2000.
26. Kazama Y, Hamamoto T, Foster DC and Kisiel W: Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation. J Biol Chem 270: 66-72, 1995.
27. Suzuki M, Kobayashi H, Tanaka Y, Hirashima Y, Kanayama N, Takei Y, Saga Y, Suzuki M, Itoh H and Terao T: Bikunin target genes in ovarian cancer cells identified by microarray analysis. J Biol Chem 278: 14640-14646, 2003.
28. Suzuki M, Kobayashi H, Tanaka Y, Kanayama N and Terao T: Reproductive failure in mice lacking inter-alpha-trypsin inhibitor (ITI)-ITI target genes in mouse ovary identified by microarray analysis. J Endocrinol 183: 29-38, 2004.
29. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR and Reed JC: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56: 2422-2427, 1996.
30. Yamamoto K, Ichijo H and Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 19: 8469-8478, 1999.